Current Report Filing (8-k)
April 23 2018 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): April 18, 2018
Amarin Corporation plc
(Exact name of registrant as specified in its charter)
|
|
|
|
|
England and Wales
|
|
0-21392
|
|
Not applicable
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
2 Pembroke House, Upper Pembroke Street
28-32,
Dublin
2,
Ireland
|
|
Not applicable
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: +353 1 6699 020
Not Applicable
Former
name or former address, if changed since last report
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule
12b-2
of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
Emerging growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On April 23, 2018, Amarin Corporation plc (the Company)
announced that Aaron Berg had been promoted to the position of Senior Vice President, Chief Commercial Officer. Mr. Berg previously served the Company as Senior Vice President, Marketing and Sales. Mr. Berg joined the Company in November
of 2012.
Mr. Berg is an industry veteran. Before joining Amarin, Mr. Berg served as President and Chief Executive Officer
for Essentialis, Inc., a development stage pharmaceutical company where he led the companys work on triglyceride management. Prior to joining Essentialis, Mr. Berg served as Vice President of Marketing
and Sales at Kos Pharmaceuticals (Kos), where he was instrumental in driving annual revenues approaching $1 billion. Mr. Berg worked at Kos until it was acquired by Abbott Laboratories in December 2006 for
$3.7 billion. Mr. Berg began his pharmaceutical industry career as a sales representative with Bristol-Myers Squibb, followed by various commercial positions with Schering-Plough and GlaxoSmithKline.
In connection with the promotion of Mr. Berg to Chief Commercial Officer, Mark Salyer, who previously served as Senior Vice President and
Chief Commercial Officer, has separated from the Company effective April 18, 2018. Mr. Salyer will receive the severance and other separation benefits set forth in his employment agreement, a copy of which is attached as Exhibit 10.1 to
this Current Report on Form
8-K.
A press release regarding the foregoing is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
*
|
Management contract or compensatory plan or arrangement.
|
* *
*
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: April 23, 2018
|
|
|
|
Amarin Corporation plc
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ John Thero
|
|
|
|
|
|
|
John Thero
|
|
|
|
|
|
|
President and Chief Executive Officer
|
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024